modelA10BD01

Diagram of A10BD01

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:PhenforminAndSulfonylureas
ATC code:A10BD01
route:oral
compartments:1
dosage:50mg
volume of distribution:1.5L
clearance:200mL/min
other parameters in model implementation

Phenformin and sulfonylureas (ATC code A10BD01) is a fixed-dose combination previously used in the management of type 2 diabetes mellitus. Phenformin is a biguanide-class antihyperglycemic agent, while sulfonylureas stimulate insulin secretion from pancreatic beta cells. Phenformin was withdrawn in many countries due to risk of lactic acidosis, and the combination is not currently approved or in regular clinical use.

Pharmacokinetics

No published pharmacokinetic model with quantitative parameters for the fixed-dose combination phenformin and sulfonylureas with ATC code A10BD01 was found. Thus, no referenced population pharmacokinetic data are available. Estimates here are based on typical oral pharmacokinetics for each drug class separately and assumed for the combination, with standard adult population as target.

References

  1. Scheen, AJ, & Lefèbvre, PJ (1995). Antihyperglycaemic agents. Drug interactions of clinical importance. Drug safety 12(1) 32–45. DOI:10.2165/00002018-199512010-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7741982

  2. Marchetti, P, et al., & Navalesi, R (1991). Pharmacokinetic optimisation of oral hypoglycaemic therapy. Clinical pharmacokinetics 21(4) 308–317. DOI:10.2165/00003088-199121040-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/1760902

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)